Proton pump inhibitor formulations for adults
Pro Research Analysisby 
Searched over 200M research papers
Proton Pump Inhibitor Formulations for Adults: Types and Innovations
Proton pump inhibitors (PPIs) are widely used to treat conditions related to excessive gastric acid secretion in adults. The most common formulations available are oral tablets and capsules, but there are ongoing efforts to develop new dosage forms to address stability, dosing flexibility, and patient-specific needs .
Oral Formulations: Tablets, Capsules, and Advanced Oral Technologies
The majority of commercial PPI preparations in the US and EU are enteric-coated tablets and capsules. These coatings protect the drug from degradation in the acidic environment of the stomach, ensuring it reaches the intestine for absorption. However, the poor stability of PPIs in acidic conditions remains a challenge, making it difficult to create formulations that allow for easy dose adjustments .
Recent advances include the development of minitablets, pellets, bilayer tablets, floating tablets, and mucoadhesive tablets. These novel oral formulations aim to improve drug stability, control release profiles, and enhance patient compliance .
Alternative and Novel Delivery Systems: Nanoparticles, Parenteral, and Transdermal Forms
Researchers are exploring alternative delivery systems such as nanoparticles and microparticles to further protect PPIs from degradation and potentially allow for targeted delivery. Additionally, parenteral (injectable), transdermal (patch), and rectal preparations are being investigated to provide options for patients who cannot take oral medications, such as those who are critically ill or have swallowing difficulties Srebro2022Johnson2008.
Enteral Administration in Hospitalized and Critically Ill Adults
In inpatient settings, especially among critically ill adults, alternative PPI formulations are often required due to the inability to swallow tablets or capsules. Liquid suspensions and formulations suitable for administration via feeding tubes are used in these cases, ensuring effective acid suppression and prevention of stress-related mucosal bleeding .
Pharmacokinetics, Pharmacodynamics, and Patient-Specific Considerations
The effectiveness of PPIs depends on their absorption and activation, which can be influenced by age, genetics, and the specific formulation used. These factors affect the time to reach maximum concentration and the duration of acid suppression. Prolonged use, especially at higher doses, is common among older adults, but this practice is associated with increased risks of adverse effects Belei2020Hálfdánarson2018Maes2017+2 MORE.
Safety, Long-Term Use, and Deprescribing in Adults
Long-term PPI use in adults, particularly older adults, has been linked to several adverse effects, including increased risks of fractures, infections, nutrient deficiencies, kidney disease, and possibly higher mortality rates. Many patients are prescribed PPIs without a valid indication or for longer durations and higher doses than recommended. Studies suggest that deprescribing—either discontinuing or reducing the dose—can be safely considered in a significant proportion of adult patients, especially during hospitalizations Hálfdánarson2018Maes2017Song2023+2 MORE.
Conclusion
Proton pump inhibitor formulations for adults have evolved from standard enteric-coated tablets and capsules to include a range of advanced oral and alternative delivery systems. These innovations aim to address challenges related to drug stability, dosing flexibility, and patient-specific needs. However, careful consideration of long-term use and regular evaluation for deprescribing are essential to minimize potential adverse effects, especially in older adults. Ongoing research continues to expand the options for safe and effective PPI therapy in diverse adult populations Srebro2022Johnson2008Belei2020+5 MORE.
Sources and full results
Most relevant research papers on this topic
Enteral administration of three proton-pump-inhibitor formulations.
Enteral administration of three proton-pump inhibitor formulations effectively prevents stress-related mucosal bleeding in critically ill patients.
DOI